dc.contributor.author |
Webster, R |
en |
dc.contributor.author |
Patel, A |
en |
dc.contributor.author |
Selak, Vanessa |
en |
dc.contributor.author |
Billot, L |
en |
dc.contributor.author |
Bots, ML |
en |
dc.contributor.author |
Brown, A |
en |
dc.contributor.author |
Bullen, Christopher |
en |
dc.contributor.author |
Cass, A |
en |
dc.contributor.author |
Crengle, S |
en |
dc.contributor.author |
Elley, Carolyn |
en |
dc.contributor.author |
Grobbee, DE |
en |
dc.contributor.author |
Neal, B |
en |
dc.contributor.author |
Peiris, D |
en |
dc.contributor.author |
Poulter, N |
en |
dc.contributor.author |
Prabhakaran, D |
en |
dc.contributor.author |
Rafter, N |
en |
dc.contributor.author |
Stanton, A |
en |
dc.contributor.author |
Stepien, S |
en |
dc.contributor.author |
Thom, S |
en |
dc.contributor.author |
Usherwood, T |
en |
dc.contributor.author |
Wadham, A |
en |
dc.contributor.author |
Rodgers, A |
en |
dc.contributor.author |
SPACE Collaboration |
en |
dc.date.accessioned |
2016-02-02T23:26:10Z |
en |
dc.date.available |
2015-12-12 |
en |
dc.date.issued |
2016-02-15 |
en |
dc.identifier.citation |
International Journal of Cardiology, 2016, 205 pp. 147 - 156 (10) |
en |
dc.identifier.issn |
0167-5273 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/28179 |
en |
dc.description.abstract |
Aims: To conduct a prospective, individual participant data (IPD) meta-analysis of randomised controlled trials comparing a polypill-based approach with usual care in high risk individuals. Methods and results: Three trials comparing polypill-based care with usual care in individuals with CVD or high calculated cardiovascular risk contributed IPD. Primary outcomes were self-reported adherence to combination therapy (anti-platelet, statin and ≥two blood pressure (BP) lowering agents), and difference in mean systolic BP (SBP) and LDL-cholesterol at 12months. Analyses used random effects models. Among 3140 patients from Australia, England, India, Ireland, New Zealand and The Netherlands (75% male, mean age 62years), median follow-up was 15months. At baseline, 84%, 87% and 61% respectively were taking a statin, anti-platelet agent and at least two BP lowering agents. At 12months, compared to usual care, participants in the polypill arm had higher adherence to combination therapy (80% vs. 50%, RR 1.58; 95% CI, 1.32 to 1.90; p<0.001), lower SBP (-2.5mmHg; 95% CI, -4.5 to -0.4; p=0.02) and lower LDL-cholesterol (-0.1mmol/L; 95% CI, -0.2 to 0.0; p=0.04). Baseline treatment levels were a major effect modifier for adherence and SBP (p-homog <0.0001 and 0.02 respectively) with greatest improvements seen among those under-treated at baseline. Conclusions: Polypill therapy significantly improved adherence, SBP and LDL-cholesterol in high risk patients compared with usual care, especially among those who were under-treated at baseline. |
en |
dc.description.uri |
http://www.ncbi.nlm.nih.gov/pubmed/26736090 |
en |
dc.format.medium |
Print-Electronic |
en |
dc.language |
English |
en |
dc.publisher |
Elsevier |
en |
dc.relation.ispartofseries |
International Journal of Cardiology |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0167-5273/
https://www.elsevier.com/about/company-information/policies/sharing |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Meta-analysis |
en |
dc.subject |
Polypill |
en |
dc.subject |
Secondary prevention |
en |
dc.subject |
Cardiovascular disease |
en |
dc.title |
Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1016/j.ijcard.2015.12.015 |
en |
pubs.begin-page |
147 |
en |
pubs.volume |
205 |
en |
dc.rights.holder |
Copyright:
Elsevier |
en |
dc.identifier.pmid |
26736090 |
en |
pubs.author-url |
http://www.sciencedirect.com/science/article/pii/S0167527315310081 |
en |
pubs.end-page |
156 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
516917 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Population Health |
en |
pubs.org-id |
Epidemiology & Biostatistics |
en |
pubs.org-id |
Gen.Practice& Primary Hlthcare |
en |
pubs.org-id |
Pacific Health |
en |
dc.identifier.eissn |
1874-1754 |
en |
pubs.record-created-at-source-date |
2016-02-03 |
en |
pubs.dimensions-id |
26736090 |
en |